Summary: Dupilumab, a fully human anti-interleukin-4 receptor alfa (IL-4Ralfa) monoclonal antibody, inhibits interleukin 4 (IL-4) and interleukin 13 (IL-13) signaling, key drivers of type-2-mediated inflammation. Dupilumab was recently registered as an add-on therapy for patients with inadequately controlled moderate to severe atopic dermatitis and asthmatics with severe disease that remains uncontrolled despite high-dose inhaled corticosteroids plus long-acting β2-agonists. A number of clinical trials have proved the efficacy and safety of dupilumab in patients with these atopic diseases.